Atropine nitrate | 7459-97-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Atropine nitrate
• 英文别名: (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;nitric acid
• CAS: 7459-97-4
• 化学式: C17H24N2O6
• 分子量: 352.4
• InChiKey: MJYHSOCPRKVNKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.58
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING<br/>[FR] COMPOSÉS ET COMPOSITIONS AMÉLIORANT LA COGNITION, MÉTHODES DE PRÉPARATION ET MÉTHODES DE TRAITEMENT
  申请人：MITHRIDION INC

  公开号：WO2012033956A1

  公开（公告）日：2012-03-15

  The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

  该发明通常涉及对可用于刺激肌碱受体和治疗认知障碍的肌碱激动剂。本文披露的肌碱激动剂包括噁唑二唑衍生物组合物及其制剂。还提供了合成噁唑二唑化合物的方法。本公开还涉及部分用于增强诸如人类等受试者认知功能的组合物。该组合物包括肌碱激动剂或其药学适宜形式。本公开还涉及通过给予这种组合物来治疗动物如人类的方法。
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR CONDITIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES OCULAIRES
  申请人：ALLERGAN INC

  公开号：WO2020219707A1

  公开（公告）日：2020-10-29

  The present invention is related to topical ophthalmic compositions comprising one or more active components. The active components in the topical ophthalmic compositions include, but are not limited to atropine, oxymetazoline, brimonidine, epinephrine, clonidine, carbachol, neostigmine, demecarium, isoflurophate, phospholine iodide, aceclidine, Formula I, and pharmaceutically acceptable salts thereof. Moreover, the topical ophthalmic compositions may include a buffer and do not contain a viscosity-enhancing component. Also described herein are methods for the treatment of ocular conditions and for the improvement of vision parameters using the topical ophthalmic compositions.